NobleGen Biosciences holds exclusive license from Harvard and BU to commercialize breakthrough fourth-generation nanopore sequencing technology. Boston University Professor Amit Meller, an internationally recognized leader in nanopore physics, developed the technology. He has won $8.5 million in NIH funding since 2002. NobleGen is run by Meller and CEO Frank Feist and operates out of UMass Boston’s Venture Development Center.
NobleGen’s technology is designed to be 100x faster than the best projected performance of 3rd generation sequencing. For more information contact Sean Lee (firstname.lastname@example.org).